Home > 시장보고서 > 메디컬디바이스 > 체외진단장치(IVD) > High-Growth Diagnostic Testing Markets

전화 문의

시장보고서

High-Growth Diagnostic Testing Markets

리서치사	Trimark Publications
발행일	2008년 11월	상품코드	77978
페이지 정보	310 pages
가격	US $ 3,400 ￦ 4,050,400 PDF by E-mail (Single User License) US $ 6,800 ￦ 8,100,800 PDF By E-mail (Unlimited User License)

한글목차
영문목차
관련자료

영문목차

Abstract

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments.

The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

1. Overview

1.1 Statement of Report
1.2 Scope of this Report
1.3 Methodology
1.4 Executive Summary

2. Sector Overview

2.1 Global Diagnostic Products Industry

3. High-Growth Testing Markets: Market Segment Analysis: Size, Growth and Share

3.1 Global High-Growth Diagnostic Testing Markets
- 3.1.1 Market Drivers in the High-Growth Diagnostics Testing Sector
- 3.1.2 Market Segments for High-Growth Testing
- 3.1.3 Key Players in the High-Growth Diagnostics Testing Segment
- 3.1.4 High-Growth Testing Sector Analysis
3.2 U.S. High-Growth Testing Market
- 3.2.1 Market Overview
- 3.2.2 Diagnostic Test Categories
3.3 European High-Growth Diagnostic Test Market
- 3.3.1 German Diagnostic Markets
- 3.3.2 U.K. Testing Diagnostic Market
  - 3.3.2.1 U.K. Market Statistics
  - 3.3.2.2 U.K. Competitive Analysis
  - 3.3.2.3 U.K. Market Access
3.4 Japanese Diagnostic Testing Market
3.5 Chinese Diagnostic Testing Market

4. High-Growth Testing Individual Markets

4.1 Hepatitis Serologic Markers and Nucleic Acid Testing
- 4.1.1 Hepatitis B Virus (HBV)
- 4.1.2 Hepatitis C Virus (HCV) Testing
- 4.1.3 Hepatitis B Virus/Hepatitis C Virus Viral Load and Drug Resistance

5. Cardiac Markers

5.1 Market Overview
- 5.1.1 American Market
- 5.1.2 European Market
5.2 Acute Myocardial Infarction
5.3 Heart Failure (BNP)
- 5.3.1 Market Overview
- 5.3.2 Commercial Assays for BNP and NT-proBNP
- 5.3.3 Market Share
5.4 CRP
5.5 Pulmonary Embolism (D-dimer Test)
5.6 Key Players

6. Cytogenetic Testing

6.1 Cancer Testing
6.2 Prenatal Testing and Cytogenetics
- 6.2.1 Cystic Fibrosis Testing
  - 6.2.1.1 CF Testing Methodology
  - 6.2.1.2 CF Screening Technology Summary
6.3 Key Players in Segment

7. Fertility Testing

8. Clinical Laboratory Genomics

8.1 Introduction
8.2 Clinical Laboratory Genomics Testing
8.3 Developments in Clinical Laboratory Genomics
- 8.3.1 Nucleic Acid Amplification Techniques
- 8.3.2 Chromosome Imaging
- 8.3.3 Genomics Technologies
- 8.3.4 Proteomics Technology
- 8.3.5 Current Pharmacogenomic Tests
- 8.3.6 Future Pharmacogenomic Testing

9. Glucose Monitoring

9.1 Overview of Market Segment
9.2 Competitive Strategies
9.3 Analyses of the Current Market Conditions, Competition and Product Mix
- 9.3.1 First-Generation Monitors
- 9.3.2 Second-Generation Monitors
- 9.3.3 Third-Generation SMBG Technologies
- 9.3.4 Other Monitoring Device Advancements

10. Cancer Biomarker Testing

10.1 Segment Overview
10.2 The Cancer Testing Market
10.3 Competition
10.4 Individual Markets
- 10.4.1 Cancer Pathology: Testing
  - 10.4.1.1 Rare Cell/Micro Metastasis Detection
  - 10.4.1.2 Cancer Pathology: High-Throughput Screening
  - 10.4.1.3 Competition
  - 10.4.1.4 Drivers
- 10.4.2 Breast Cancer
  - 10.4.2.1 CA 15-3
  - 10.4.2.2 CA 27-29
  - 10.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes
  - 10.4.2.4 Estrogen and Progesterone Receptor (ER and PR)
  - 10.4.2.5 HER-2
  - 10.4.2.6 Herceptin
  - 10.4.2.7 p53
  - 10.4.2.8 NMP66
  - 10.4.2.9 Mammastatin
  - 10.4.2.10 Drivers for Breast Cancer Test Development
- 10.4.3 Ovarian Cancer
  - 10.4.3.1 CA 125 IItrade;
  - 10.4.3.2 BRCA1 and BRCA2
  - 10.4.3.3 Steroid Hormone Receptors
  - 10.4.3.4 Epidermal Growth Factor Receptor (EGFR)
  - 10.4.3.5 Lysophospholipids
- 10.4.4 Cervical Cancer
- 10.4.5 Colon Cancer DNA Testing
10.5 Pharmacogenomic Cancer Testing

11. HPV Testing

11.1 Overview
11.2 U.S. Market
11.3 European Market
11.4 Other Markets
11.5 The Association of HPV and Cervical Cancer
11.6 Assays for HPV

12. Biochips for Clinical Applications

12.1 Roche AmpliChip
12.2 Amersham CodeLink
12.3 Breast Cancer DNA Chips
12.4 Osmetech eSensor
12.5 Affymetrix GeneChip System 3000Dx v.2
12.6 Caliper and Cepheid
12.7 Agilent Technologies 2100 Lab-on-a-Chip

13. HIV

13.1 U.S. Testing Market
13.2 World Testing Market
- 13.2.1 Asia
- 13.2.2 Japan
- 13.2.3 Sub-Saharan Africa
- 13.2.4 Rest of World
13.3 Major Players

14. Cellular Imaging Cytopathology and Histopathology

14.1 Segment Overview
14.2 The Market
14.3 Market Drivers
14.4 Market Restraints
14.5 Cytology and Histology Technology Platforms
- 14.5.1 Cytology Screening Procedures and Pap Smear Technology
- 14.5.2 Histology
- 14.5.3 Market Drivers
- 14.5.4 ISH Staining
- 14.5.5 Special-Stains Staining
14.6 Third-Party Reimbursement
14.7 Competition

15. Infectious Disease Testing

15.1 Streptococcus Testing
15.2 Chlamydia Testing
15.3 Mononucleosis
15.4 Gonorrhea
15.5 Influenza
15.6 Malaria
15.7 Tuberculosis
15.8 Methicillin-Resistant Staphylococcus aureus (MRSA)

16. High-Growth Testing Diagnostic Trends

16.1 Genetic Testing
16.2 Quality Measures
16.3 Moderators of Growth
- 16.3.1 Diagnostics and the Aging Population
- 16.3.2 Individualized Medicine
- 16.3.3 Genetic Testing
16.4 Workforce Issues
16.5 Reimbursement
- 16.5.1 Cardiovascular
- 16.5.2 Screening for Diabetes
- 16.5.3 CPT Test Codes and Payment Amounts
16.6 Rapid Near-Patient Testing in Hospitals
16.7 Satellite Facilities
16.8 Regionalization of Laboratory Care
16.9 Requirements for High-Growth Testing
16.10 Clinical Laboratory Improvement Act (CLIA)

17. Business Trends in the Industry

17.1 Sector Consolidation
17.2 Diagnostic Testing Growth Trends
17.3 Acquisition, License Agreements, Internal Development, Partnerships
17.4 Product Testing Depth in High-Growth Testing
17.5 Government Regulation
- 17.5.1 U.S. Regulations
  - 17.5.1.1 Importing Medical Devices into the U.S.
  - 17.5.1.2 Exporting Medical Devices from the U.S.
- 17.5.2 U.K Regulations
- 17.5.3 E.U. Regulations
- 17.5.4 Japanese Regulations
17.6 Increased Market Penetration in High-Growth Testing

18. Important Technology Trends

19. Company Profiles

19.1 Accurex Biomedical, Pvt., Ltd.
19.2 Adeza Biomedical Corporation (Hologic)
19.3 Agilent Technologies, Inc.
19.4 Ambri, Ltd.
19.5 American Bio Medica Corp.
19.6 Ani Biotech
19.7 Applied Spectral Imaging
19.8 Avitar, Inc.
19.9 Axis-Shield
19.10 Bayer Corporation
19.11 Beckman Coulter
19.12 Becton Dickinson
19.13 Biomerica
19.14 Bio-Rad, Inc.
19.15 Cozart Bioscience
19.16 Denka Seiken Co., Ltd.
19.17 diaDexus LLC
19.18 Enterix, Inc. (Subsidiary of Quest Diagnostics)
19.19 Genetix
19.20 Genzyme Diagnostics
19.21 Hologic, Inc.
19.22 Iatron
19.23 Inverness Medical Innovations
19.24 Jiangnan Biotech
19.25 Johnson & Johnson
19.26 Kyowa Medex Co., Ltd.
19.27 LifePoint, Inc.
19.28 LifeScan
19.29 Matritech
19.30 Medix Biochemica
19.31 Myriad Genetics
19.32 OraSure
19.33 Pheromone Sciences
19.34 Polymedco
19.35 Procrea
19.36 QIAGEN
19.37 Quidel
19.38 Roche Diagnostics
19.39 Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)
19.40 Shionogi & Co.
19.41 Siemens
19.42 Spectral Diagnostics, Inc.
19.43 Third Wave Technologies

20. Appendix 1: Opportunities in the Chinese Biotech Market

21. Appendix 2: Opportunities in the Indian Diagnostics Market

INDEX OF TABLES

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments
Table 1.2: Market Trends in the High-Growth Diagnostics Space
Table 2.1: U.S. Population Dynamics, 2005-2015
Table 2.2: World Population and Growth, 2000-2025
Table 2.3: Total Japanese Population and Aging Demographics Forecast
Table 2.4: Worldwide Market Share In Vitro Diagnostic Companies, 2007
Table 2.5: Worldwide In Vitro Diagnostics Market Size, 2003-2012
Table 2.6: U.S. In Vitro Central Lab Diagnostic Testing, 2003-2012
Table 2.7: Worldwide Near-Patient Diagnostic Testing, 2002-2012
Table 3.1: High-Growth Market Segments Overview, 2008
Table 3.2: U.S. High-Growth Diagnostic Testing Market Segments, 2007
Table 3.3: Regional Comparison of GDP, Healthcare and IVD, 2006
Table 3.4: German Diagnostics Products Market Sales, 2000-2008
Table 3.5: The German Patient Care Lab Test Market, 2002-2012
Table 3.6: The German Alternate Site Testing Market (POL), 2002-2012
Table 3.7: The German Hospital Point of Care Market, 2002-2012
Table 3.8: German Clinical Diagnostic Rapid Test Market Segments
Table 3.9: List of Diagnostics Companies in the U.K.
Table 3.10: Major U.K. IVD Manufacturers
Table 3.11: U.S. IVD Manufacturers Doing Business in the U.K.
Table 3.12: Other European Companies That Manufacture IVD Products in the U.K.
Table 3.13: Japanese In Vitro Diagnostic Testing Market, 2000-2012
Table 3.14: Japan' s Diagnostics Market Sales, 1997-2006
Table 3.15: Companies with Leading Market Share of Japanese Diagnostics, by Segment
Table 3.16: Chinese Diagnostics Products Market Sales, 2000-2012
Table 3.17: Disease Burden in China: Urban and Rural
Table 4.1: Global Market for HBV Diagnostic Testing, 2000-2012
Table 4.2: U.S. Market for HBV Diagnostic Testing, 2000-2012
Table 4.3: Serological Diagnosis of Hepatitis B Virus Infections
Table 4.4: Lower Detection Limits of HBV DNA Assays
Table 4.5: Summary of Hepatitis B Test Technology
Table 4.6: Global Market for HCV Diagnostic Testing, 2000-2008
Table 4.7: U.S. Market for HCV Diagnostic Testing, 2000-2008
Table 4.8: Efficiency of Available HCV Screening Tests
Table 4.9: Recommendations for Diagnostic Testing for Hepatitis C
Table 4.10: Hepatitis C Statistics
Table 4.11: Gen-Probe Clinical Diagnostic Products Test for the Detection of HCV
Table 5.1: Biomarkers in Heart Failure
Table 5.2: Medication Chart for Cardiovascular Disease
Table 5.3: Acute Myocardial Infarction Facts
Table 5.4: Emergency Room Admissions in the U.S., 1997-2005
Table 5.5: Market Growth Drivers for Cardiac Markers
Table 5.6: Market Barriers to Growth for Cardiac Markers
Table 5.7: Specific Cardiac Markers
Table 5.8: Cardiac Markers after Onset of Myocardial Infarction
Table 5.9: The Cardiac Marker Market for Testing in the U.S., 2001-2010
Table 5.10: Market Share of Cardiac Marker Segment
Table 5.11: U.S. Market for Point of Care Cardiac Marker Testing, 2000-2010
Table 5.12: BNP Characteristics
Table 5.13: Global Sales of BNP Diagnostic Tests, 2000-2010
Table 5.14: Market Share of BNP Assays in the U.S.
Table 5.15: Market Share of NT-proBNP Assays in the U.S.
Table 5.16: Cardiovascular Risk Classification by CRP Level
Table 5.17: Clinical Characteristics of D-dimer
Table 6.1: Global Market for Cancer Cytogenetic Diagnostic Testing, 2000-2012
Table 6.2: U.S. Market for Cancer Cytogenetic Diagnostic Testing, 2000-2012
Table 6.3: Genetic Testing: Consequences and Challenges
Table 6.4: CF Carrier Risk by Ethnic Group
Table 6.5: Reasons for CF Testing
Table 6.6: CF Gene Detection Rates Vary by Ethnic Background
Table 6.7: Global Market for CF Diagnostic Testing, 2000-2010
Table 6.8: U.S. Market for CF Diagnostic Testing, 2000-2010
Table 6.9: Commercial CF Screening Products
Table 6.10: Emerging CF Screening Products
Table 7.1: The Fertility Testing Market in the U.S., 2000-2008
Table 9.1: U.S. Population of Diabetics by Group
Table 9.2: Percentage of U.S. Adults Using Diabetes Medication, by Age, 1997-2006
Table 9.3: Health Care Utilization by the Diabetes Patient
Table 9.4: The Global Population of Persons with Diabetes, 1995 and 2025
Table 9.5: Market for Glucose Testing in the U.S., 2001-2012
Table 9.6: The Worldwide Market for Glucose Testing, 2000-2012
Table 9.7: Major Players in Point of Care and Near-Patient Testing for OTC Glucose Meters
Table 10.1: Women' s Cancer Incidence Estimates in the U.S., 2008
Table 10.2: Five-Year Disease-Free Survival by Stage at Diagnosis
Table 10.3: TPA Marker Sensitivity
Table 11.1: HPV Risk Factors
Table 11.2: HPV and Cervical Carcinoma
Table 11.3: Global HPV-Testing Market Size, 2003-2011
Table 11.4: HPV and Cervical Carcinoma Risk
Table 11.5: Reflex HPV Testing with Cytology
Table 11.6: Predictability of HPV Test by Abnormal Pap Smear Type
Table 11.7: Incidence of Cervical Cancer and Cytological Abnormalities
Table 11.8: Long-Term Trends in HPV Testing
Table 12.1: Biochip Revenues and Growth Rates by Application
Table 12.2: Total Biochip Market: Worldwide Revenue Forecasts, 2000-2010
Table 12.3: Total Biochip Market: U.S. Revenue Forecasts, 2000-2010
Table 13.1: AIDS Statistics for the U.S.: Diagnoses, Deaths and Burden, 2002-2006
Table 13.2: U.S. HIV Statistics, 2007
Table 13.3: Births of HIV Infected Babies in U.S., 2000-2009
Table 13.4: Rapid HIV Tests on the Market
Table 13.5: U.S. High-Growth Testing Market for HIV, 2001-2012
Table 13.6: Global HIV Statistics, 2007
Table 14.1: Estimated Cervical Cancer Cases/Deaths Worldwide
Table 14.2: Medicare Reimbursement for Cervical Pathology Procedures
Table 15.1: U.S. Strep Testing Market Size, 2000-2008
Table 15.2: Rapid Strep Tests on the Market
Table 15.3: U.S. Market for Rapid Point of Care Strep Tests
Table 15.4: The U.S. Chlamydia Testing Market, 2001-2009
Table 15.5: Rapid Tests for Chlamydia
Table 15.6: Rapid Tests for Gonorrhea
Table 15.7: Commercially-Available Rapid Tests for Malaria
Table 15.8: FIND Partners
Table 15.9: Global Market Potential for TB Diagnostic Testing, 2000-2010
Table 15.10: MRSA Diagnostics Currently on the Market
Table 16.1: New CPT Test Codes Introduced in 2008
Table 18.1: Employment of Clinical Laboratory Workers, 2006-2016
Table 20.1: China Biotech Reagents Market
Table 20.2: Biotechnology Projects Between China and the West
Table 21.1: Overview of Healthcare in India

INDEX OF FIGURES

Figure 2.1: U.S. Lab Industry Market Share, 2007
Figure 2.2: Major Lab Testing Segments, U.S.
Figure 3.1: Total Spending on Healthcare in the U.S., 2007
Figure 3.2: International Per Capita Spending on Healthcare, 2006
Figure 3.3: Japan IVD Sales by Segment, 2006
Figure 14.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females
Figure 15.1: Global Incidence of Malaria
Figure 15.2: Mode of Action of Common Malaria RDT Format
Figure 15.3: FIND Pipeline for TB Diagnostics
Figure 21.1: Indian Diagnostics Market Segments, 2007

한글목차
영문목차
관련자료

이용안내 회사소개 이용약관 사이트맵

TEL: 02-2025-2992
E-mail: koreainfo@gii.co.jp